Inflammation

Chemical pollutants can change your skin bacteria and increase your eczema risk − new research explores how

Retrieved on: 
화요일, 4월 23, 2024

Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.

Key Points: 
  • Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.
  • Some studies have found rates of eczema in developing nations to be over thirtyfold lower compared with industrialized nations.
  • Scientists know that factors such as diets rich in processed foods as well as exposure to specific detergents and chemicals increase the risk of developing eczema.
  • Living near factories, major roadways or wildfires increase the risk of developing eczema.

There’s something in the air

  • Then we looked at databases from the U.S. Environmental Protection Agency to see which chemicals were most common in those areas.
  • Diisocyanates were first manufactured in the U.S. around 1970 for the production of spandex, nonlatex foam, paint and polyurethane.
  • The manufacture of xylene also increased around that time, alongside an increase in the production of polyester and other materials.
  • After 1975, when all new cars became outfitted with a new technology that converted exhaust gas to less toxic chemicals, isocyanate and xylene both became components of automobile exhaust.
  • How directly exposing mice to these toxins compares to the typical levels of exposure in people is still unclear.

Skin microbiome and pollution

  • Every person is coated with millions of microorganisms that live on the skin, collectively referred to as the skin microbiome.
  • You’ve probably seen moisturizers and other skin products containing ceramides, a group of lipids that play an important role in protecting the skin.
  • To see which toxins could prevent production of the beneficial lipids that prevent eczema, my team and I used skin bacteria as canaries in the coal mine.
  • Lysine helps protect the bacteria from the harms of the toxins but doesn’t provide the health benefits of ceramides.
  • Bacteria that help keep skin healthy could live on any fabric, but, just as with air pollution, the amount of beneficial lipids they made dropped to less than half the levels made when grown on fabrics like cotton.

Addressing pollution’s effects on skin

  • Detectors capable of sensing low levels of isocyanate or xylene could help track pollutants and predict eczema flare-ups across a community.
  • Better detectors can also help researchers identify air filtration systems that can scrub these chemicals from the environment.
  • In the meantime, improving your microbial balance may require avoiding products that limit the growth of healthy skin bacteria.
  • I believe that it may one day allow us to get back to a time when these diseases were uncommon.


Ian Myles receives funding from the Department of Intramural Research at the National Institute of Allergy and Infectious Diseases. He is the author of, and receives royalties for, the book GATTACA Has Fallen: How population genetics failed the populace. Although he is the co-discoverer of Roseomonas mucosa RSM2015 for eczema, he has donated the patent to the public and has no current conflict of interest for its sales.

Good news: midlife health is about more than a waist measurement. Here’s why

Retrieved on: 
금요일, 4월 19, 2024

During the appointment they measure your waist.

Key Points: 
  • During the appointment they measure your waist.
  • GPs and health professionals commonly measure waist circumference as a vital sign for health.
  • Men are at greatly increased risk of health issues if their waist circumference is greater than 102 centimetres.
  • More than two-thirds of Australian adults have waist measurements that put them at an increased risk of disease.

How much is too much?

  • A ratio of 0.6 or more places a person at the highest risk of disease.
  • This can kick off a discussion about their risk of chronic diseases and how they might address this.
  • For women, hormone levels begin changing in mid-life and this also stimulates increased fat levels particularly around the abdomen.
  • Finally, your family history and genetics can make you predisposed to gaining more abdominal fat.

Why the waist?

  • Visceral fat surrounds and infiltrates major organs such as the liver, pancreas and intestines, releasing a variety of chemicals (hormones, inflammatory signals, and fatty acids).
  • These affect inflammation, lipid metabolism, cholesterol levels and insulin resistance, contributing to the development of chronic illnesses.
  • In addition to the direct effects of hormone changes, declining levels of oestrogen change brain function, mood and motivation.
  • These psychological alterations can result in reduced physical activity and increased eating – often of comfort foods high in sugar and fat.
  • And importantly, the waist circumference (and ratio to height) is just one measure of human health.

Muscle matters

  • On current evidence, it is equally or more important for health and longevity to have higher muscle mass and better cardiorespiratory (aerobic) fitness than waist circumference within the healthy range.
  • So, if a person does have an excessive waist circumference, but they are also sedentary and have less muscle mass and aerobic fitness, then the recommendation would be to focus on an appropriate exercise program.
  • Conversely, a person with low visceral fat levels is not necessarily fit and healthy and may have quite poor aerobic fitness, muscle mass, and strength.

Getting moving is important advice

  • Exercise can counter a lot of the negative behavioural and physiological changes that are occurring during midlife including for people going through menopause.
  • And regular exercise reduces the tendency to use food and drink to help manage what can be a quite difficult time in life.
  • Measuring your waist circumference and monitoring your weight remains important.


Rob Newton receives funding from National Health and Medical Research Council, the Medical Research Future Fund, Cancer Council Western Australia, Spinal Cord Injuries Australia and the World Cancer Research Fund. Rob Newton is a board member of The Healthy Male.

Caring for older Americans’ teeth and gums is essential, but Medicare generally doesn’t cover that cost

Retrieved on: 
금요일, 4월 19, 2024

As dentistry scholars, we believe Koop also deserves credit for something else.

Key Points: 
  • As dentistry scholars, we believe Koop also deserves credit for something else.
  • Americans who rely on the traditional Medicare program for their health insurance get no help from that program with paying their dental bills aside from some narrow exceptions.
  • This group includes some 24 million people over 65 – about half of all the people who rely on Medicare for their health insurance.

‘Medically necessary’ exceptions

  • The list of circumstances that would lead patients to be eligible is short.
  • Some examples include patients scheduled for organ transplants or who have cancer treatment requiring radiation of their jaws.
  • But we believe that dental care is necessary for everyone, especially for older people.

Chew, speak, breathe

  • While many working Americans get limited dental coverage through their employers, those benefits are usually limited to as little as $1,000 per year.
  • And once they retire, Americans almost always lose even that basic coverage.
  • Rich Americans with Medicare coverage are almost three times more likely to receive dental care compared to those with low incomes.

Connected to many serious conditions

  • Having diabetes makes you three times as likely to develop gum disease because diabetes compromises the body’s response to inflammation and infection.
  • At the same time, treating diabetes patients for gum disease can help control their blood sugar levels.

Chemo can damage your teeth


Many cancer treatments can damage teeth, especially for older adults. As a result, Medicare has started to reimburse for dental bills tied to tooth decay or other oral conditions after they get chemotherapy or radiation treatment.

More than nice to have

  • Doctors and dentists are educated separately, and doctors learn very little about dental conditions and treatments when they’re in medical school.
  • Most dental electronic health records aren’t linked to medical systems, hindering comprehensive care and delivery of dental care to those in need.
  • Medical insurance was designed specifically to cover large, unpredictable expenses, while dental insurance was intended to mainly fund predictable and lower-cost preventive care.

Medicare Advantage plans

  • Until Medicare expands coverage to include preventive dental services for everyone, alternative plans such as Medicare Advantage, through which the federal government contracts with private insurers to provide Medicare benefits, serve as a stopgap.
  • In 2016, only 21% of beneficiaries in traditional Medicare had purchased a stand-alone dental plan, whereas roughly two-thirds of Medicare Advantage enrollees had at least some dental benefits through their coverage.


Frank Scannapieco is affiliated with The Task Force on Design and Analysis in Oral Health Research, and consults for the Colgate-Palmolive Company. Ira Lamster is a member of the Santa Fe Group. He currently receives consulting fees from Colgate, and research support from the CareQuest Institute.

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Retrieved on: 
목요일, 4월 18, 2024

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Key Points: 


Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Retrieved on: 
목요일, 4월 18, 2024

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
목요일, 4월 18, 2024

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Retrieved on: 
수요일, 4월 10, 2024

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Key Points: 
  • Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
    The issuer is solely responsible for the content of this announcement.
  • » Adjusted consolidated EBITDA margin: 27.3%
    Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023.
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) declined by 13.8% to EUR 310.2 million (prior-year period: EUR 359.8 million).
  • We exceeded our guidance for consolidated revenue and reached the upper end of the forecast range for adjusted EBITDA.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
월요일, 4월 8, 2024

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
화요일, 4월 2, 2024

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
화요일, 4월 9, 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.